Good MorningEquity markets drifted higher on Thursday, buoyed by Walmart's results despite a cautious outlook. The retailer reported a better-than-expected quarter and reaffirmed guidance, stating consumers would begin to feel the impact of tariffs by the end of the current quarter.
The S&P 500 is poised to retest record highs, but whether conditions are strong enough to push it further may hinge on NVIDIA’s upcoming Q1 earnings report later this month. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Communication Services | |
Despite mounting challenges in 2025, Wall Street and institutional investors continue to express strong confidence in Alphabet (NASDAQ: GOOGL).
While the stock has faced significant pressure this year, Alphabet is at a technical and fundamental turning point.
After bouncing off support around... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Staples | |
Walmart’s (NYSE: WMT) stock price is set for a big move due to underlying strengths, market positioning, guidance, high potential for positive catalysts, and analysts' sentiment.
The analysts' sentiment trends ahead of the FQ1 2026 earnings report were bullish, leading this market to new ... Read the Full Story |
|
Consumer Discretionary | |
Average investors focus on the next year or two for a company they consider buying for their portfolios, but those who can keep a longer time horizon in mind stand out above the crowd. There are several examples of legendary value investors who don’t often move their money around, but every ... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
Microsoft Corporation (NASDAQ: MSFT) and OpenAI have announced that they are looking to reset their partnership. The reset is the latest chapter in a story that’s been building between the two companies for the last six years. In this case, it should be profitable for MSFT stock.
The part... Read the Full Story |
|
Technology | |
Over approximately the last three weeks, markets have been on the rise big-time. The S&P 500 closed just under $5,900 on May 14, just around 4% lower than the all-time high it reached in February. As market sentiment shifts, Broadcom (NASDAQ: AVGO), a leading semiconductor stock, has emerged... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Industrials | |
For security and defense company Axon Enterprise (NASDAQ: AXON), Q1 earnings were exactly what it needed to take its 2025 returns from decent to delightful.
The company’s results massively impressed markets, leading to shares rising over 14% afterwards. The broadly positive effects of the... Read the Full Story |
|
Consumer Discretionary | |
After months of hiding in the shadows, National Vision Holdings Inc. (NASDAQ: EYE) is suddenly one of the hottest stocks in the market.
Shares have jumped more than 40% over the past week alone, hitting their highest level in more than a year as momentum builds behind a stock that had been trad... Read the Full Story |
|
Technology | |
Intel Corporation (NASDAQ: INTC) and Shell plc (NYSE: SHEL) unveiled a technological collaboration on May 14, 2025, with Intel officially certifying Shell's immersion cooling fluids for use with its Xeon processors in data centers.
This development positions Shell's solution as the first from a... Read the Full Story |
|
Consumer Discretionary | |
It’s been a mostly bullish earnings season for casino stocks with names like MGM Resorts International (NYSE: MGM) and Las Vegas Sands Corp. (NYSE: LVS) having posted solid earnings. But the third time wasn’t a charm for Bally’s Corp. (NYSE: BALY).
Bally’s is part of the... Read the Full Story |
|
Finance | |
The financial markets are full of clues and queues for investors to consider when they are looking for the next path forward in their portfolios. Though some of these factors aren’t as clear-cut as watching a price chart move around certain technical levels, they’re a bit more intricat... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. | | View Today's Stock Pick |
|
